Quell Therapeutics: Valuation, Funding & Investors
80 Wood Lane, Translation & Innovation Hub, Imperial College White City Campus, London, London W12 0BZ, GBhttps://www.quell-tx.com/Therapeutics
Quell Therapeutics is a biotechnology company developing engineered regulatory T cell (Treg) therapies aimed at treating autoimmune and inflammatory diseases. The company employs a cell‑engineering platform to generate and optimize antigen‑specific Tregs designed to restore immune tolerance and achieve targeted, durable immune regulation with reduced broad immunosuppression.
Leadership & Board
- Current Number of Employees
- 106
- Current LinkedIn Followers
- 21,926
Latest Estimated Valuation
- Total Amount Raised
- $156M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $156M
- Latest Funding Round
- Series B
Employee Trend
Quell Therapeutics had 106 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
106Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Quell Therapeutics had 21,926 followers as of November 9, 2026. The number of followers increased by 63 (0.29%) week-over-week.
21,926Latest Followers Count
63(0.29%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 29, 2021 | Series B | $156.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| SV Health Investors | Series B |
| Fidelity | Series B |
Similar Companies
A snapshot of private companies similar to Quell Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
